Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Focused Ultrasound-enabled Brain Tumor Liquid Biopsy.

Zhu L, Cheng G, Ye D, Nazeri A, Yue Y, Liu W, Wang X, Dunn GP, Petti AA, Leuthardt EC, Chen H.

Sci Rep. 2018 Apr 26;8(1):6553. doi: 10.1038/s41598-018-24516-7.

2.

Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient.

Miller CA, Dahiya S, Li T, Fulton RS, Smyth MD, Dunn GP, Rubin JB, Mardis ER.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002444. doi: 10.1101/mcs.a002444. Print 2018 Apr.

3.

T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma.

Woroniecka K, Chongsathidkiet P, Rhodin KE, Kemeny HR, Dechant CA, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson CC, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, Bigner DD, Giles AJ, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE.

Clin Cancer Res. 2018 Feb 7. pii: clincanres.1846.2017. doi: 10.1158/1078-0432.CCR-17-1846. [Epub ahead of print]

PMID:
29437767
4.

Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma.

Zolkind P, Przybylski D, Marjanovic N, Nguyen L, Lin T, Johanns T, Alexandrov A, Zhou L, Allen CT, Miceli AP, Schreiber RD, Artyomov M, Dunn GP, Uppaluri R.

Oncotarget. 2017 Dec 28;9(3):4109-4119. doi: 10.18632/oncotarget.23751. eCollection 2018 Jan 9.

5.

Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress.

Gelman SJ, Naser F, Mahieu NG, McKenzie LD, Dunn GP, Chheda MG, Patti GJ.

Cell Rep. 2018 Jan 9;22(2):512-522. doi: 10.1016/j.celrep.2017.12.050.

6.

Erratum: Genomic landscape of high-grade meningiomas.

Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, A Ducar M, Thorner AR, van Hummelen P, O Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R.

NPJ Genom Med. 2017 Sep 4;2:26. doi: 10.1038/s41525-017-0023-6. eCollection 2017.

7.

Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma.

Mahlokozera T, Vellimana AK, Li T, Mao DD, Zohny ZS, Kim DH, Tran DD, Marcus DS, Fouke SJ, Campian JL, Dunn GP, Miller CA, Kim AH.

Neuro Oncol. 2018 Mar 27;20(4):472-483. doi: 10.1093/neuonc/nox232.

PMID:
29244145
8.

Management of intracranial melanomas in the era of precision medicine.

Young GJ, Bi WL, Wu WW, Johanns TM, Dunn GP, Dunn IF.

Oncotarget. 2017 Jul 13;8(51):89326-89347. doi: 10.18632/oncotarget.19223. eCollection 2017 Oct 24. Review.

9.

Direct puncture Onyx embolization of a large calvarial metastasis with intracranial extension: Case report.

Zhou MH, Dunn GP, Osbun JW, Cross DT 3rd, Moran CJ, Dacey RG Jr, Kansagra AP.

Interv Neuroradiol. 2018 Apr;24(2):220-224. doi: 10.1177/1591019917740353. Epub 2017 Nov 9.

PMID:
29119877
10.

Comprehensive Analysis of Hypermutation in Human Cancer.

Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A.

Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19.

11.

Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.

Mei Y, Du Z, Hu C, Greenwald NF, Abedalthagafi M, Agar NYR, Dunn GP, Bi WL, Santagata S, Dunn IF.

Cell Commun Signal. 2017 Sep 18;15(1):34. doi: 10.1186/s12964-017-0189-7.

12.

Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.

Johanns TM, Bowman-Kirigin JA, Liu C, Dunn GP.

Neurosurgery. 2017 Sep 1;64(CN_suppl_1):165-176. doi: 10.1093/neuros/nyx321. No abstract available.

PMID:
28899059
13.

Genomic landscape of high-grade meningiomas.

Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, Ducar M, Thorner AR, van Hummelen P, Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R.

NPJ Genom Med. 2017;2. pii: 15. doi: 10.1038/s41525-017-0014-7. Epub 2017 Apr 26. Erratum in: NPJ Genom Med. 2017 Sep 4;2:26.

14.

Free ammonia offers algal crop protection from predators in dairy wastewater and ammonium-rich media.

Thomas PK, Dunn GP, Passero M, Feris KP.

Bioresour Technol. 2017 Nov;243:724-730. doi: 10.1016/j.biortech.2017.07.008. Epub 2017 Jul 5.

PMID:
28711800
15.

Genomic profile of human meningioma cell lines.

Mei Y, Bi WL, Greenwald NF, Agar NY, Beroukhim R, Dunn GP, Dunn IF.

PLoS One. 2017 May 26;12(5):e0178322. doi: 10.1371/journal.pone.0178322. eCollection 2017.

16.

Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.

Johanns TM, Dunn GP.

Cancer J. 2017 Mar/Apr;23(2):125-130. doi: 10.1097/PPO.0000000000000247. Review.

17.

Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.

Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, Nussenbaum B, Paniello RC, Rich JT, Diaz JA, Michel LP, Wildes T, Dunn GP, Zolkind P, Kallogjeri D, Piccirillo JF, Dehdashti F, Siegel BA, Chernock RD, Lewis JS Jr, Adkins DR.

Clin Cancer Res. 2017 May 1;23(9):2186-2194. doi: 10.1158/1078-0432.CCR-16-1469. Epub 2016 Nov 9.

18.

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.

Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, Ansstas G, Mardis ER, Dunn GP.

Cancer Discov. 2016 Nov;6(11):1230-1236. Epub 2016 Sep 28.

19.

Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.

Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP.

Cancer Immunol Res. 2016 Dec;4(12):1007-1015. Epub 2016 Oct 31.

20.

Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1.

Law JM, Stark SC, Liu K, Liang NE, Hussain MM, Leiendecker M, Ito D, Verho O, Stern AM, Johnston SE, Zhang YL, Dunn GP, Shamji AF, Schreiber SL.

ACS Med Chem Lett. 2016 Aug 18;7(10):944-949. eCollection 2016 Oct 13.

21.

Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.

Zolkind P, Dunn GP, Lin T, Griffith M, Griffith OL, Uppaluri R.

Oral Oncol. 2017 Aug;71:169-176. doi: 10.1016/j.oraloncology.2016.09.010. Epub 2016 Oct 14. Review.

PMID:
27751760
22.

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.

Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, Woodmansee WW, Reardon DA, Freeman GJ, Fecci PE, Laws ER Jr, Santagata S, Dunn GP, Dunn IF.

Oncotarget. 2016 Nov 22;7(47):76565-76576. doi: 10.18632/oncotarget.12088.

23.

High incidence of TERT mutation in brain tumor cell lines.

Johanns TM, Fu Y, Kobayashi DK, Mei Y, Dunn IF, Mao DD, Kim AH, Dunn GP.

Brain Tumor Pathol. 2016 Jul;33(3):222-7. doi: 10.1007/s10014-016-0257-5. Epub 2016 Mar 9.

24.

Genomic landscape of intracranial meningiomas.

Bi WL, Abedalthagafi M, Horowitz P, Agarwalla PK, Mei Y, Aizer AA, Brewster R, Dunn GP, Al-Mefty O, Alexander BM, Santagata S, Beroukhim R, Dunn IF.

J Neurosurg. 2016 Sep;125(3):525-35. doi: 10.3171/2015.6.JNS15591. Epub 2016 Jan 15.

PMID:
26771848
25.

Shared decision-making for the elderly patient with a surgical condition.

Dunn GP.

Br J Surg. 2016 Jan;103(2):e19-20. doi: 10.1002/bjs.10076. Epub 2015 Dec 15. No abstract available.

PMID:
26667318
26.

Principles of immunology and its nuances in the central nervous system.

Dunn GP, Okada H.

Neuro Oncol. 2015 Nov;17 Suppl 7:vii3-vii8. doi: 10.1093/neuonc/nov175. Review.

27.

A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells.

Mao DD, Gujar AD, Mahlokozera T, Chen I, Pan Y, Luo J, Brost T, Thompson EA, Turski A, Leuthardt EC, Dunn GP, Chicoine MR, Rich KM, Dowling JL, Zipfel GJ, Dacey RG, Achilefu S, Tran DD, Yano H, Kim AH.

Cell Rep. 2015 Jun 23;11(11):1809-21. doi: 10.1016/j.celrep.2015.05.027. Epub 2015 Jun 11.

28.

Surgical Revascularization in North American Adults with Moyamoya Phenomenon: Long-Term Angiographic Follow-up.

Arias EJ, Dunn GP, Washington CW, Derdeyn CP, Chicoine MR, Grubb RL Jr, Moran CJ, Cross DT 3rd, Dacey RG Jr, Zipfel GJ.

J Stroke Cerebrovasc Dis. 2015 Jul;24(7):1597-608. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.053. Epub 2015 May 9.

29.

Surgery, palliative care, and the American College of Surgeons.

Dunn GP.

Ann Palliat Med. 2015 Jan;4(1):5-9. doi: 10.3978/j.issn.2224-5820.2015.01.03.

30.

Molecular and cellular heterogeneity: the hallmark of glioblastoma.

Aum DJ, Kim DH, Beaumont TL, Leuthardt EC, Dunn GP, Kim AH.

Neurosurg Focus. 2014 Dec;37(6):E11. doi: 10.3171/2014.9.FOCUS14521. Review.

PMID:
25434380
31.

Stereotactic laser ablation of high-grade gliomas.

Hawasli AH, Kim AH, Dunn GP, Tran DD, Leuthardt EC.

Neurosurg Focus. 2014 Dec;37(6):E1. doi: 10.3171/2014.9.FOCUS14471. Review.

PMID:
25434378
32.

The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.

Luo LY, Kim E, Cheung HW, Weir BA, Dunn GP, Shen RR, Hahn WC.

Mol Cancer Res. 2015 Mar;13(3):502-9. doi: 10.1158/1541-7786.MCR-14-0407. Epub 2014 Nov 3.

33.

Emerging insights into barriers to effective brain tumor therapeutics.

Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H.

Front Oncol. 2014 Jul 21;4:126. doi: 10.3389/fonc.2014.00126. eCollection 2014. Review.

34.

Patient-centering approaches for the surgical oncologist: palliative care, patient navigation, and distress screening.

Dunn GP, Miller N.

J Surg Oncol. 2014 Oct;110(5):621-8. doi: 10.1002/jso.23713. Epub 2014 Jul 3. Review.

PMID:
24995436
35.

Spontaneous Resorption of a Penetrating Orbital Bone Fracture Fragment.

Campbell AA, Cunnane ME, Dunn GP, Gray ST, Lefebvre DR.

Ophthalmic Plast Reconstr Surg. 2015 Sep-Oct;31(5):e123-5. doi: 10.1097/IOP.0000000000000146.

PMID:
24833452
36.

A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease.

Onken MD, Winkler AE, Kanchi KL, Chalivendra V, Law JH, Rickert CG, Kallogjeri D, Judd NP, Dunn GP, Piccirillo JF, Lewis JS Jr, Mardis ER, Uppaluri R.

Clin Cancer Res. 2014 Jun 1;20(11):2873-84. doi: 10.1158/1078-0432.CCR-14-0205. Epub 2014 Mar 25.

37.

Three-dimensional brain surface visualization for epilepsy surgery of focal cortical dysplasia.

Yang JC, Aronson JP, Dunn GP, Codd PJ, Buchbinder BR, Eskandar EN.

J Clin Neurosci. 2014 Jul;21(7):1230-2. doi: 10.1016/j.jocn.2013.12.004. Epub 2013 Dec 13.

PMID:
24485033
38.

In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.

Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, Beroukhim R, Drapkin R, Hahn WC.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1102-7. doi: 10.1073/pnas.1311909111. Epub 2014 Jan 2.

39.

Structure and ubiquitination-dependent activation of TANK-binding kinase 1.

Tu D, Zhu Z, Zhou AY, Yun CH, Lee KE, Toms AV, Li Y, Dunn GP, Chan E, Thai T, Yang S, Ficarro SB, Marto JA, Jeon H, Hahn WC, Barbie DA, Eck MJ.

Cell Rep. 2013 Mar 28;3(3):747-58. doi: 10.1016/j.celrep.2013.01.033. Epub 2013 Feb 28.

40.

Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th annual Frye-Halloran Brain Tumor Symposium.

Jones PS, Dunn GP, Barker FG 2nd, Curry WT, Hochberg FH, Cahill DP.

Neurosurg Focus. 2013 Feb;34(2):E9. doi: 10.3171/2012.12.FOCUS12349. Review.

PMID:
23373454
41.

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.

Dunn GP, Andronesi OC, Cahill DP.

Neurosurg Focus. 2013 Feb;34(2):E2. doi: 10.3171/2012.12.FOCUS12355. Review.

PMID:
23373447
42.

Emerging insights into head and neck cancer metastasis.

Allen CT, Law JH, Dunn GP, Uppaluri R.

Head Neck. 2013 Nov;35(11):1669-78. doi: 10.1002/hed.23202. Epub 2012 Dec 22. Review.

PMID:
23280716
43.

Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1.

Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z.

J Neurosurg. 2013 Jan;118(1):142-8. doi: 10.3171/2012.9.JNS101610. Epub 2012 Oct 26.

PMID:
23101443
44.

Palliative surgical outcomes: are we looking through a keyhole?

Dunn GP.

Ann Surg Oncol. 2012 Nov;19(12):3637-8. doi: 10.1245/s10434-012-2507-z. No abstract available.

PMID:
22825771
45.

Emerging insights into the molecular and cellular basis of glioblastoma.

Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC.

Genes Dev. 2012 Apr 15;26(8):756-84. doi: 10.1101/gad.187922.112. Review.

46.

Update on surgical palliative care.

Dunn GP.

Anesthesiol Clin. 2012 Mar;30(1):xiii-xiv. doi: 10.1016/j.anclin.2011.11.006. No abstract available.

PMID:
22405438
47.

Surgical palliative care: recent trends and developments.

Dunn GP.

Anesthesiol Clin. 2012 Mar;30(1):13-28. doi: 10.1016/j.anclin.2011.11.001. Review.

PMID:
22405429
48.

Cancer immunoediting in malignant glioma.

Dunn GP, Fecci PE, Curry WT.

Neurosurgery. 2012 Aug;71(2):201-22; discussion 222-3. doi: 10.1227/NEU.0b013e31824f840d. Review.

PMID:
22353795
49.

Dual ipsilateral craniotomies through a single incision for the surgical management of multiple intracranial aneurysms.

Dunn GP, Nahed BV, Walcott BP, Jung H, Tierney TS, Ogilvy CS.

World Neurosurg. 2012 Mar-Apr;77(3-4):502-6. doi: 10.1016/j.wneu.2011.07.005. Epub 2011 Nov 7.

PMID:
22120339
50.

ERK1/2 regulation of CD44 modulates oral cancer aggressiveness.

Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R.

Cancer Res. 2012 Jan 1;72(1):365-74. doi: 10.1158/0008-5472.CAN-11-1831. Epub 2011 Nov 15.

Supplemental Content

Support Center